Overview

A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate cancer (CRPC).

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborators:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Antibodies, Monoclonal